$5.10
-0.13[-2.49%]
At close: Apr 22
$5.10
0[0.00%]
After Hours: 7:01AM EDT
Lyra Therapeutics
(NASDAQ:LYRA)Latest News for Lyra Therapeutics Stock (NASDAQ:LYRA)
Lyra Therapeutics Stock (NASDAQ: LYRA)
Categories: All
Wednesday, April 17, 2024
Monday, March 25, 2024
Friday, March 22, 2024
Tuesday, November 14, 2023
Friday, October 06, 2023
Monday, October 02, 2023
Tuesday, September 12, 2023
- B of A Securities Maintains Buy on Lyra Therapeutics, Raises Price Target to $15Benzinga Newsdesk - Sep 12, 2023, 10:58AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Sep 12, 2023, 9:06AM
- Lyra Therapeutics shares are trading higher after the company announced its BEACON Phase 2 study of LYR-220 for chronic rhinosinusitis in patients with prior ethmoid sinus surgury met its primary endpoint.Benzinga Newsdesk - Sep 12, 2023, 8:56AM
- Market-Moving News for September 12thBenzinga Newsdesk - Sep 12, 2023, 8:35AM
- Lyra Therapeutics Shares Resume TradeBill Haddad - Sep 12, 2023, 7:32AM
- Lyra Therapeutics' BEACON Phase 2 Study Of LYR-220 For Chronic Rhinosinusitis In Patients With Prior Ethmoid Sinus Surgery Met Its Primary EndpointBenzinga Newsdesk - Sep 12, 2023, 7:03AM
Thursday, August 31, 2023
Thursday, July 13, 2023
Tuesday, June 27, 2023
Tuesday, June 20, 2023
Friday, May 26, 2023
Friday, May 12, 2023
Tuesday, April 25, 2023
Thursday, March 30, 2023
Monday, March 27, 2023
Tuesday, February 07, 2023
Monday, February 06, 2023
Monday, December 19, 2022
Monday, December 12, 2022
Thursday, December 08, 2022
Wednesday, November 30, 2022
Tuesday, November 08, 2022
Wednesday, October 26, 2022
- Lyra Therapeutics Says Concluded There Is Material Weakness In Internal Control Over Financial Reporting Related To Accounting For Certain Complex, Nonrecurring TransactionsMichael Horton - Oct 26, 2022, 5:22PM
- Audit Committee Of Lyra Therapeutics Board Says Prior Q1, Q2 Financial Statements Should No Longer Be Relied Upon, Says Intends To Restate Prior Financial StatementsMichael Horton - Oct 26, 2022, 5:21PM
Tuesday, September 13, 2022
- Important Biotech Catalysts For September 13, 2022 - End Of The Day SummaryRagothaman Srinivasan - Sep 13, 2022, 6:45PM
- Lyra's Mid-Stage Chronic Rhinosinusitis Candidate Study Progressed, Shares FallRagothaman Srinivasan - Sep 13, 2022, 9:56AM
- Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial Of LYR-220 In Post-Surgical Chronic Rhinosinusitis Patients To Randomized Stage Of StudyBill Haddad - Sep 13, 2022, 7:01AM